Media headlines about Invuity (NASDAQ:IVTY) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Invuity earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 47.8138768292262 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several equities research analysts have recently commented on IVTY shares. Northland Securities restated a “buy” rating and issued a $13.00 price objective on shares of Invuity in a research note on Tuesday, September 26th. Piper Jaffray Companies restated a “buy” rating and issued a $12.00 price objective on shares of Invuity in a research note on Friday, November 10th. ValuEngine upgraded Invuity from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Zacks Investment Research upgraded Invuity from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $11.67.

Shares of Invuity (NASDAQ:IVTY) opened at $7.85 on Thursday. The company has a debt-to-equity ratio of 5.39, a quick ratio of 2.47 and a current ratio of 2.90. Invuity has a 12 month low of $5.70 and a 12 month high of $9.70.

Invuity (NASDAQ:IVTY) last posted its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.04. Invuity had a negative return on equity of 212.38% and a negative net margin of 111.43%. The firm had revenue of $9.60 million during the quarter, compared to analyst estimates of $9.87 million. equities analysts anticipate that Invuity will post -2.41 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Invuity (IVTY) Share Price” was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at

About Invuity

Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.

Insider Buying and Selling by Quarter for Invuity (NASDAQ:IVTY)

Receive News & Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related companies with's FREE daily email newsletter.